Neuroone Medical Technologies is trading 7.16% up at $0.92 in pre-market after its 8:00 a.m. ET October 29 announcement of peer-reviewed initial OneRF trigeminal nerve ablation results. - 14 of 15 patients were immediately pain-free; all 15 had favorable outcomes at a mean six-month follow-up. - The small, retrospective study does not establish what drove the move; healthcare-sector strength contrasted with lower major U.S. index futures. - October 28 close: $0.86.